| US 7,425,546 B2 | ||
| Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders | ||
| Ernest G. Seidman, Côte St. Luc (Canada); and Yves Theoret, Montreal (Canada) | ||
| Assigned to Hopital Sainte-Justine, Montreal, Quebec (Canada) | ||
| Filed on Mar. 22, 2007, as Appl. No. 11/690,073. | ||
| Application 11/690073 is a continuation of application No. 11/420694, filed on May 26, 2006. | ||
| Application 11/420694 is a continuation of application No. 11/152866, filed on Jun. 14, 2005, granted, now 7,105,497. | ||
| Application 11/152866 is a continuation of application No. 10/703920, filed on Nov. 06, 2003, granted, now 6,987,097. | ||
| Application 10/703920 is a continuation of application No. 10/034456, filed on Dec. 27, 2001, granted, now 6,680,302. | ||
| Application 10/034456 is a continuation of application No. 09/288344, filed on Apr. 08, 1999, granted, now 6,355,623. | ||
| Claims priority of provisional application 60/101714, filed on Sep. 24, 1998. | ||
| Prior Publication US 2007/0197554 A1, Aug. 23, 2007 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/70 (2006.01); A61K 31/52 (2006.01); A61K 31/415 (2006.01) | ||
| U.S. Cl. 514—45 [514/46; 514/47; 514/48; 514/262; 514/391; 514/395] | 20 Claims |
| 1. A method for the treatment of an immune-mediated gastrointestinal disorder or a non-IBD autoimmune disease, said method
comprising:
(a) administering azathioprine or 6-mercaptopurine to a subject having an immune-mediated gastrointestinal disorder or a non-IBD
autoimmune disease;
(b) determining a level of 6-thioguanine present in said subject from red blood cells;
(c) indicating that said determined level of 6-thioguanine is associated with a higher likelihood of response when said determined
level of 6-thioguanine is between about 230 pmol per 8×108 red blood cells and about 450 pmol per 8×108 red blood cells; and
(d) considering said determined level of 6-thioguanine in the treatment of said subject.
|